Radiological evaluation with Computed Tomography in the diagnosis of Medication-Related Osteonecrosis of the Jaw (MRONJ): RAD-ONJ observational study. A preliminary report of the study population
https://doi.org/10.4081/wpph.2023.9786
Accepted: 6 September 2023
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Background and Aims: Osteonecrosis of the Jaw (ONJ), recently renamed Medication-Related Osteonecrosis of the Jaw (MRONJ), is a recently recognized disease (2003), characterized by alterations including clinical signs and symptoms (not limited to bone exposure) together with jawbone radiological destruction, better assessed by Computed Tomography (CT) scan. We designed an observational (retrospective and prospective) study to systematically investigate the rate of occurrence of the various radiological signs of CT semeiotics, predefined in an appropriate table (i.e., focal and diffuse osteosclerosis, sequestrum, cortical disruption, periosteal reaction, osteolysis, etc.) in patients with MRONJ, diagnosed according to the criteria of the Italian SICMF-SIPMO recommendations (2020). Results: since March 2022, 120 patients with MRONJ were examined; 5 were considered not eligible due to lack of adequate CT images. Clinical data and radiological features of 115 patients were recorded and are under examination. Conclusions: the sample was higher than expected, and it appears sufficient to proceed to the evaluation of radiological features and draw conclusions about the investigated issue.
Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws-2009 Update. J Oral Maxillofac Surg. 2009;67:2-12. DOI: https://doi.org/10.1016/j.joms.2009.01.009
Ruggiero SL, Dodson TB, Fantasia J, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw - 2014 update. J Oral Maxillofac Surg. 2014;72:1938-56. DOI: https://doi.org/10.1016/j.joms.2014.04.031
Campisi G, Fedele S, Fusco V, et al. Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Futur Oncol. 2014;10:257-75. DOI: https://doi.org/10.2217/fon.13.211
Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus. J Bone Miner Res. 2015;30:3-23. DOI: https://doi.org/10.1002/jbmr.2524
Otto S, Marx RE, Tröltzsch M, et al. Comments on "diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus". J Bone Miner Res. 2015;30:1113-5. DOI: https://doi.org/10.1002/jbmr.2525
Yarom N, Shapiro CL, Peterson DE, et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37:2270-90. DOI: https://doi.org/10.1200/JCO.19.01186
Fusco V, Santini D, Campisi G, et al. Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary. JCO Oncol Pract. 2020;16:142-5. DOI: https://doi.org/10.1200/JOP.19.00645
Schiodt M, Otto S, Fedele S, et al. Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges. Oral Dis. 2019;25:1815-21. DOI: https://doi.org/10.1111/odi.13160
Campisi G, Bedogni A, Fusco V. Raccomandazioni clinico-terapeutiche sull’osteonecrosi delle ossa mascellari (ONJ) farmaco-relata e sua prevenzione. 2020. Available from: https://www.sipmo.it/raccomandazioni-clinico-terapeutiche-sullosteonecrosi-delle-ossa-mascellari-associata-a-bisfosfonati-e-sua-prevenzione/
Bedogni A, Fusco V, Di Fede O, et al. Re: Medication-Related Osteonecrosis of the Jaw (MRONJ). J Oral Maxillofac Surg 2022;80:2-3. DOI: https://doi.org/10.1016/j.joms.2021.09.021
Fusco V, Campisi G, Bedogni A. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ). Support Care Cancer. 2022;30:7047-51. DOI: https://doi.org/10.1007/s00520-022-06982-y
Ruggiero SL, Dodson TB, Aghaloo T, et al. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg. 2022;80:920-43. DOI: https://doi.org/10.1016/j.joms.2022.02.008
Campisi G, Mauceri R, Bedogni A, Fusco V. Re: AAOMS Position Paper on Medication-Related Osteonecrosis of the Jaw-2022 Update. J Oral Maxillofac Surg. 2022;80:1723-4. DOI: https://doi.org/10.1016/j.joms.2022.07.149
Fusco V, Mauceri R, Campisi G, Bedogni A. Re: American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update: Quantitative Risk Assessment and Controversial Issues. J Oral Maxillofac Surg. 2022;80:1871-3. DOI: https://doi.org/10.1016/j.joms.2022.07.143
Bedogni A, Mauceri R, Fusco V, et al. Italian Position Paper (SIPMO-SICMF) on Medication-Related Osteonecrosis of the Jaw (MRONJ). 2023. Available from: https://www.qeios.com/read/PBUJ6Z
Kumar SKS., Meru MC., Sedghizadeh PP. Osteonecrosis of the jaws secondary to bisphosphonate therapy: A case series. J Contemp Dent Pract. 2008;9:063-9. DOI: https://doi.org/10.5005/jcdp-9-1-63
Bedogni A, Fusco V, Agrillo A, Campisi G. Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ). Oral Dis. 2012;18:621-3. DOI: https://doi.org/10.1111/j.1601-0825.2012.01903.x
Copyright (c) 2024 Antonella Fasciolo, Riccardo Campora, Vittorio Fusco, Costanza Massarino, Francesca Marengo, Giorgia Rossetti, Paola Brigo, Ivan Gallesio, Luca Benzi, Maura Rossi, Federico Monaco, Marco Ladetto, Antonio Maconi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
